Supportivtherapie in der gynäkologischen Onkologie - Teil 1

Andreas Löhr; Andreas du Bois

doi:10.1055/s-2004-817988

Geburtshilfe und Frauenheilkunde, Table of Contents

Geburtshilfe Frauenheilkd 2003; 63(6): R113-R136
DOI: 10.1055/s-2004-817988

GebFra-Refresher

Georg Thieme Verlag Stuttgart · New York

Supportivtherapie in der gynäkologischen Onkologie - Teil 1

Andreas Löhr¹ , Andreas du Bois¹

¹Klinik für Gynäkologie und gynäkologische Onkologie, Dr.-Horst-Schmidt-Kliniken GmbH, Wiesbaden

Abstract

Full Text

References

Literatur

1 Mollenkopf A, du Bois A, Meerpohl H G. Sequentieller Verlauf und prospektives Management bei Ifosfamid-induzierter Toxizität. Geburtsh Frauenheilk. 1996; 56 525-528
2 NCI-CTC Version 2.0. www.ctep.cancer.gov, released 30. 4. 1999. 30.4.1999
3 Hesketh P J. Defining the emetogenicity of cancer chemotherapeutic regimens: relevance to clinical practice. Oncologist. 1999; 4 191-196
4 du Bois A, Feyer P, Ortner P. Emesis in der Tumortherapie. München, Hamburg; Ellyott 1999
5 Hesketh P J, Kris M G, Grunberg S M. et al . Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997; 15 103-109
6 American Society of Clinical Oncology .Recommendations for the use of antiemetics. ASCO guidelines. www.asco.org posted 21. 6. 2002.
7 Hughes W T, Armstrong D, Bodey G P. et al . 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002; 34 730-751
8 Green M D, Koelbl H, Baselga J. et al . A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003; 14 29-35
9 Klastersky J, Paesmans M, Rubenstein E B. et al . The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000; 18 3038-3051
10 Bonadonna G, Valagussa P, Moliterni A. et al . Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995; 332 901-906
11 Ozer H, Armitage J O. et al . 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol. 2000; 18 3558-3585
12 Verhoef J. Prevention of infection in the neutropenic patient. Clin Infect Dis. 1993; 17 (Suppl 2) 359-367
13 Freifeld A, Marchigiani D, Wish T. et al . A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med. 1999; 341 305-311
14 Herbrecht R, Denning D W, Patterson T F. et al . Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002; 347 408-415
15 Mock V, Piper B, Sabbatini P. et al . National Comprehensive Cancer Network fatigue practice guidelines. Oncology. 2000; 14 151-161
16 Fyles A W, Milosevic M, Pintilie M. et al . Anemia, hypoxia and transfusion in patients with cervix cancer: a review. Radiother Oncol. 2000; 57 13-19
17 Casadevall N, Nataf J, Viron B. et al . Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 1998; 339 578-583
18 Rizzo J D, Lichtin A E, Woolf S H. et al . Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002; 20 4083-4107
19 Dührsen U. Gibt es Indikationen für Erythropoetin in der Onkologie. Dtsch Aerztebl. 2002; 99 A3470-3475
20 Kuter D J, Begley C G. Recombinant human thrombopoietin: basic biology and evaluation of clinical trials. Blood. 2002; 100 3457-3469
21 Li Y, Yang C, Xia Y. et al . Thrombocytopenia caused by development of antibodies to thrombopoietin. Blood. 2001; 98 3241-3248
22 Schiffer C A, Anderson K C. et al . Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001; 19 1519-1538
23 Vorstand und wissenschaftlicher Beirat der Bundesärztekammer (Hrsg) .Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. Köln; Deutscher Ärzteverlag 2001
24 Heimdahl A. Prevention and management of oral infections in cancer patients. Support Care Cancer. 1999; 7 224-228
25 Mahood D J, Dose A M, Loprinzi C L. et al . Inhibition of 5-fluorouracil-induced mucositis by oral cryotherapy. J Clin Oncol. 1991; 9 449-452
26 Rocke L K, Loprinzi C L, Lee J K. et al . A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer. 1993; 72 2234-2238
27 Mead G M. Management of oral mucositis associated with cancer chemotherapy. Lancet. 2002; 359 815-816
28 Schöffski P. Prävention und Therapie von Enteritis und Diarrhö bei Tumorpatienten. Schmoll HJ, Höffken K, Possinger K Kompendium internistische Onkologie. Teil 1. 3. Aufl. Berlin, Heidelberg, New York; Springer 1999: 1638-1652
29 Dodd M J, Dibble S L, Miaskowski C. Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2000; 90 39-47